Hot Topics


Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?:

KEI intervention, SCCR 29, December 9, 2014

Below is a cleaned up version of the transcript, from my rambling intervention for KEI on the broadcasting treaty definitions.

Thank you, Mr. Chairman. My comments would be initially on the definitions.

It is our position that it's more appropriate to provide protection for free services that are traditionally provided by radio and television and less appropriate for pay services,

Broadcasters make sweeping demands on scope and rights in new WIPO treaty

To understand the negotiations this week at the WIPO SCCR 29, it is helpful to review an April 2014 document, endorsed by several broadcasting organizations.

The attached document* is a joint statement by 12 broadcasting organizations, on "THE OBJECTIVES, SPECIFIC SCOPE AND OBJECT OF THE PROPOSED WIPO BROADCASTERS' TREATY".

SCCR 29 December 9, 2014: 3 secret broadcasting treaty charts ?

The December 9, 2014 SCCR morning session started with the Chair's summary of yesterday informals. The delegates discussed 3 charts. The first chart called "a technological platforms chart" is supposed to clarify the scope of protection of the new instrument, the broadcasters' treaty. The second chart is called "a rights chart". And additionally, the Chair prepared a third chart which was called a definitions chart, which contained the definitions of broadcasting organization, broadcasting transmission and signal.

SCCR 29 Morning Session: Is the Broadcasting Treaty crawling back?

The morning session of SCCR 29 (Dec 8-12, 2014) ended with a coffee break which will be followed by informals (that we are not allowed to report on at this point). After the usual decisions this morning i.e, Adoption of the agenda of the twenty ninth session then Accreditation of new non governmental organizations (and yes, the Program on Information Justice and Intellectual Property (PIJIP) is in!) we had the Adoption of the Report of the Twenty-Eighth Session of the Standing Committee on Copyright and Related Rights.

SCCR29: Opening statement of the European Union

IMG_2394-oliver-hall-allen-sccr29-700x518.jpgThe World Intellectual Property Organization's 29th Standing Committee on Copyright and Related Rights (SCCR) is meeting in Geneva from 8-12 December 2014. WIPO has a live stream of the proceedings; the password is sccr29. The opening statement of the European Union is contained below.

Patents with government interests, by disease, 2010 to 2013

The attached PDF file provides counts on the number of patents with various search terms in the specification (spec/"search term"), and the number of those patents that declare either government rights in the patents (govt/government), an assignment to the US government (an/"united states of america"), or both. The complete counts are in the PDF file. The queries were done by Claire Cassedy on December 5, 2014.

Save the Date - 10 December 2014: The Broadcasting Treaty: A Solution in Search of a Problem?

On Wednesday, 10 December 2014, Knowledge Ecology International (KEI) will convene a side event entitled, "The Broadcasting Treaty: A Solution in Search of a Problem?"; the event will take place in Room B of the World Intellectual Property Organization (WIPO) from 13:30 to 15:00.

The new Medicines Patent Pool license with AbbVie: good news for children living with HIV

The Medicines Patent Pool (MPP) has signed a new license with AbbVie, to expand access to pediatric formulations of lopinavir (LPV) and ritonavir (r). The details of the licenses are available here:

NIH rulemaking on transparency of clinical trials

The NIH has a notice about a proposed rule that "clarifies and expands requirements for the submission of clinical trial registration and results information to the database." Comments are due on or before February 19, 2015. We may ask the NIH to consider expanding the trials registry to include more information on the economics of clinical trials.

Here is a link to the Regulations.Gov docket for the proposed rule:!documentDetail;D=NIH-2011-0003-0003

UACT sends letter to Tufts President, Chairman of Trustees, asking questions about R&D cost study

On November 24, 2014. the Union for Affordable Cancer Treatment (UACT) sent a letter to Anthony P. Monaco, Office of the President, Tufts University, with copies to Michael Baenen, the Tufts Chief of Staff, and Peter Dolan, Chairman of the Board of Trustees for Tufts University, regarding the Tufts University press conference to announce an estimate of $2.6 billion as the R&D costs for new drugs.

The Winning Bet

Leading up to the release of Professor Joe DiMasi's latest study of the cost of drug development, KEI offered $50 to the individual who could most accurately predict the new cost for drug R&D.

We received 26 guesses, ranging from $1.157 billion to $5 billion.

Joel Lexchin's estimate ($2.47 billion) was the closest to DiMasi's number ($2.558 billion). It was also the 5th largest estimate.

A complete list of submissions is below.

Name & Guess
Charles Clift - 1.157 billion
Nicole H - 1.2 billion
Ronald Rader - 1.55 billion
Wouter Deelder - 1.655 billion

KEI comment on the new Tufts Study on Drug Development Costs

The Tuft Center for Study of Drug Development (CSDD) has just concluded a press conference, and issued a press release about their new study of drug development costs. The key number is $2.558 billion.

What to look for in the new Tufts study on drug development costs. 10 issues.

When the new Tufts study on the costs of R&D for development of a new drug is released Tuesday at 10AM, here are 10 things to look for:

Research note on oncology drugs, including trial size and orphan drug status

We will be sharing some data on 2005 to 2014 oncology approvals, including the size of the trials cited in the medical review, and the orphan status.

The spreadsheet we are working on updating is published here:

KEI Research Note: Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results

A copy of the research note is also available here as a pdf file:

KEI Research Note 2014:3

Size of Clinical Trials, data from the FDA 2010 NME and BLA approvals, preliminary results

Elizabeth Rajasingh
November 17, 2014


Syndicate content